Market Place
Sourcing Support
Monthly information on share capital and company voting rights
07 Apr 2026 //
GLOBENEWSWIRE
Cellectis Reveals 2025 Financials Result And Business Update
19 Mar 2026 //
GLOBENEWSWIRE
Monthly information on share capital and company voting rights
04 Mar 2026 //
GLOBENEWSWIRE
Monthly Share Capital and Voting Rights Update
04 Feb 2026 //
GLOBENEWSWIRE
Monthly Share Capital and Voting Rights
05 Jan 2026 //
GLOBENEWSWIRE
Monthly Update: Share Capital & Voting Rights
03 Dec 2025 //
GLOBENEWSWIRE
Monthly Information On Share Capital & Company Voting Rights
07 Nov 2025 //
GLOBENEWSWIRE
Cellectis Showcases Non-Viral Gene Therapy Data At ESGCT Congress
07 Oct 2025 //
GLOBENEWSWIRE
Monthly Information On Share Capital And Company Voting Rights
07 Oct 2025 //
GLOBENEWSWIRE
Monthly Info on Share Capital and Company Voting Rights
03 Sep 2025 //
GLOBENEWSWIRE
Monthly Information on Share Capital and Company Voting Rights
04 Jul 2025 //
GLOBENEWSWIRE
Monthly Information on Share Capital and Company Voting Rights
05 Jun 2025 //
GLOBENEWSWIRE
Monthly information on share capital and company voting rights
07 May 2025 //
GLOBENEWSWIRE
Monthly information on share capital and company voting rights
07 Apr 2025 //
GLOBENEWSWIRE
Cellectis Reports Financial Results for Q4 and Full Year 2024
13 Mar 2025 //
GLOBENEWSWIRE
Monthly information on share capital and company voting rights
06 Mar 2025 //
GLOBENEWSWIRE
Monthly information on share capital and company voting rights
04 Feb 2025 //
GLOBENEWSWIRE
Monthly information on share capital and company voting rights
08 Jan 2025 //
GLOBENEWSWIRE
Monthly information on share capital and company voting rights
04 Dec 2024 //
GLOBENEWSWIRE
Monthly information on share capital and company voting rights
06 Nov 2024 //
GLOBENEWSWIRE
Monthly information on share capital and company voting rights
02 Oct 2024 //
GLOBENEWSWIRE
Monthly information on share capital and company voting rights
04 Sep 2024 //
GLOBENEWSWIRE
Monthly information on share capital and company voting rights
05 Aug 2024 //
GLOBENEWSWIRE
Monthly information on share capital and company voting rights
05 Jul 2024 //
GLOBENEWSWIRE
Cellectis Reports Results from Shareholders Meeting Held on June 28, 2024
28 Jun 2024 //
GLOBENEWSWIRE
Monthly information on share capital and company voting rights
05 Jun 2024 //
GLOBENEWSWIRE
Cellectis™ Annual Shareholders General Meeting to be Held on June 28, 2024
29 May 2024 //
GLOBENEWSWIRE
Cellectis Reports Financial Results for First Quarter 2024
28 May 2024 //
GLOBENEWSWIRE
Cellectis to Report First Quarter 2024 Financial Results on May 28, 2024
27 May 2024 //
GLOBENEWSWIRE
Monthly information on share capital and company voting rights
16 May 2024 //
GLOBENEWSWIRE
AstraZeneca completes equity investment agreement with Cellectis
08 May 2024 //
INDINPHARMAPOST
AstraZeneca completes equity investment agreement with Cellectis
07 May 2024 //
PRESS RELEASE
Cellectis: AstraZeneca Completes Additional Equity Investment
06 May 2024 //
GLOBENEWSWIRE
Cellectis Appoints Arthur Stril as Interim Chief Financial Officer
02 May 2024 //
GLOBENEWSWIRE
Cellectis Reports Financial Results for the Fourth Quarter and Full Year 2023
29 Apr 2024 //
GLOBENEWSWIRE
Cellectis Announces Poster Presentations at the ASGCT Annual Meeting
08 Apr 2024 //
GLOBENEWSWIRE
Monthly Information on Share Capital and Company Voting Rights
04 Apr 2024 //
GLOBENEWSWIRE
Monthly information on share capital and company voting rights
04 Mar 2024 //
GLOBENEWSWIRE
Monthly information on share capital and company voting rights
02 Feb 2024 //
GLOBENEWSWIRE
Cellectis announces the drawdown of the second tranche of ‚¬15 million
16 Jan 2024 //
GLOBENEWSWIRE
Monthly information on share capital and company voting rights
08 Jan 2024 //
GLOBENEWSWIRE
Cellectis Reports Results from Shareholders Meeting Held on December 22, 2023
22 Dec 2023 //
GLOBENEWSWIRE
Cellectis shifts CAR-T manufacturing in-house
07 Dec 2023 //
ENDPTS
Monthly information on share capital and company voting rights
01 Dec 2023 //
GLOBENEWSWIRE
Cellectis™ Shareholders Meeting to be Held on December 22, 2023
17 Nov 2023 //
GLOBENEWSWIRE
Cellectis Announces the execution of the Subsequent Investment Agreement with AZ
15 Nov 2023 //
GLOBENEWSWIRE
Cellectis Reports Financial Results for Third Quarter and First Nine Months 2023
06 Nov 2023 //
GLOBENEWSWIRE
BeiGene touts Brukinsa data, Cellectis compares CAR-T to CDMO CAR-T
03 Nov 2023 //
ENDPTS
Monthly information on share capital and company voting rights
03 Nov 2023 //
GLOBENEWSWIRE
Cellectis to Present Results of NATHALI_01 and BALLI_01 Phases I Trials
02 Nov 2023 //
GLOBENEWSWIRE
Cellectis to Report Third Quarter 2023 Financial Results on November 6, 2023
01 Nov 2023 //
GLOBENEWSWIRE
Cellectis Presents Data on Multi-armored Allogeneic MUC1-CAR T-cells
31 Oct 2023 //
GLOBENEWSWIRE
Cellectis and Imagine Institute Publish A Study of a Gene Surgery Candidate
12 Oct 2023 //
GLOBENEWSWIRE
Monthly information on share capital and company voting rights
03 Oct 2023 //
GLOBENEWSWIRE
Cellectis to Present Data on Multi-armored Allogeneic MUC1-CAR T-cells
27 Sep 2023 //
GLOBENEWSWIRE
Monthly information on share capital and company voting rights
05 Sep 2023 //
GLOBENEWSWIRE
Cellectis Provides Full Report for Second Quarter 2023 Financial Results
07 Aug 2023 //
GLOBENEWSWIRE
Cellectis Provides Preliminary Financial Results for Second Quarter 2023
03 Aug 2023 //
GLOBENEWSWIRE
Monthly information on share capital and company voting rights
01 Aug 2023 //
GLOBENEWSWIRE
Cellectis to Report Second Quarter 2023 Financial Results on August 3, 2023
27 Jul 2023 //
GLOBENEWSWIRE
